SYSCID

A Systems medicine approach to chronic inflammatory diseases

Background

Chronic inflammatory diseases (CID) comprise a group of disorders of the immune system with a lifetime prevalence of over 10% in the EC and a continuously rising incidence in Western countries.

The SYSCID consortium brings together top-level European and EU-associated research teams with a strong track record in quantitative and mechanistic studies of immune-related disorders using systems-level and/or OMICs approaches (including leading roles in IHEC, ICGC, TwinsUK and Meta-HIT).

SYSCID will focus on three major CID (inflammatory bowel disease, systemic lupus erythematodes and rheumatoid arthritis) to identify a common set of unifying mechanisms that contribute to their pathogenesis. Identifying sub entities of CID via molecular biomarkers will lay the ground to develop a prediction framework for disease outcome and/or response to different therapies.

The project is coordinated by Kiel University in Germany (CAU) receives a total funding of 14.4 million Euros for a period of five years.

TwinsUK role

Contributing clinical, biochemical, transcriptomic and genetic data from over 6000 twins as well as providing expertise in the multi-omics and epidemiological analyses.

SYSCID Webpage: http://dev.syscid.eu/

Funding:

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733100.

Duration:

2017 – 2022